The Boston Biotech Survival Index: Big Fish Still Swimming, Minnows Getting Eaten

10/8/09Follow @xconomy

(Page 3 of 4)

CombinatoRx (NASDAQ:CRXX)
Cash on hand: $26.5 million
Related Xconomy coverage:
Former CEO Alexis Borisy Voices Mixed Feelings on CombinatoRx Saga
CombinatoRx Judgment Day Coming Soon, Arthritis Drug Results on the Way
CombinatoRx To Combine With Neuromed

Cubist Pharmaceuticals (NASDAQ: CBST)
Cash on hand: $474.4 million
Related Xconomy coverage:
Alnylam, Cubist Will Cooperate on RNAi Drug for Lung Infections
Cubist Agrees to Promote AstraZeneca Antibiotic

Curis (NASDAQ: CRIS)
Cash on hand: $26.8 million
Related Xconomy coverage:
Curis Gets $3M from Genentech for Ovarian Cancer Trial Initiation

Dyax (NASDAQ: DYAX)
Cash on hand: $53.1 million
Related Xconomy coverage:
Dyax Hit With FDA Drug Delay
Dyax Lands Deal to Raise $50M
FDA Committee Votes in Favor of Dyax Lead Drug for Rare Blood Disease

Genzyme (NASDAQ: GENZ)
Cash on hand: $1.05 billion
Related Xconomy coverage:
Genzyme Says Supplies of Two Enzyme Drugs Will Be Even Lower Than Previously Predicted
Genzyme’s Woes Piling Up as FDA Panel Says Data on Leukemia Drug Are Lacking
Genzyme Offers Glimpse at Growth Engine, New Drugs for High Cholesterol, Gaucher’s
Genzyme Halts Production at Allston Drug Plant After Virus Appears
Genzyme Reaching for a Slice From Biogen’s Breadbasket, Multiple Sclerosis Drugs

GTC Biotherapeutics (NASDAQ: GTCB)
Cash on hand: $4.7 million
Related Xconomy coverage:
FDA Approves First Drug Made From Bioengineered Goats
GTC Biotherapeutics Racing Against Time To Prove The Worth of Pharming, Thinks It Has the Edge

Haemonetics (NYSE: HAE)
Cash on hand: $173.8 million

To purchase a much expanded version of this report, in PDF format, click the “Add to Cart” button.
For $95,* you’ll get an assessment of each company’s financial position at the end of June compared to six months earlier, the projected length of time it can survive on its existing cash reserves, and an analysis of the strategic moves it has made to stay afloat in the current environment. Click here to see a sample entry. Add to Cart
*Price is subject to change without notice

Harvard Bioscience (NASDAQ: HBIO)
Cash on hand: $16.8 million

Helicos Biosciences (NASDAQ: HLCS)
Cash on hand: $8.4 million
Related Xconomy coverage:
Helicos Biosciences, Running Low on Cash, Snaps Up $10M Lifeline
With New Machine, Helicos Brings Personal Genome Sequencing a Step Closer
Helicos Cuts 30 Percent of Workforce
Helicos Shuffles CEOs, Names Lowy to Top Job

Hologic (NASDAQ: HOLX)
Cash on hand: $243.7 million
Related Xconomy coverage:
Third Wave Means Extra Power for Hologic

Idenix Pharmaceuticals (NASDAQ: IDIX)
Cash on hand: $51.7 million
Related Xconomy coverage:
Idenix Inks HIV Drug Deal With GSK Worth Up To $450M

Idera Pharmaceuticals (NASDAQ: IDRA)
Cash on hand: $50.5 million
Related Xconomy coverage:
Idera and Merck Extend R&D Deal
Idera Pharmaceuticals Inks Potential $400 Million Deal With Germany’s Merck

ImmunoGen (NASDAQ: IMGN)
Cash on hand: $71.1 million
Related Xconomy coverage:
Souped Up Herceptin Aims to Validate Immunogen’s Long Sought Dream Cancer Drug
ASCO Weekend Highlights, Immunogen, Antigenics, Aveo Show Off Cancer Drug Findings

Infinity Pharmaceuticals (NASDAQ: INFI)
Cash on hand: $150.4 million
Related Xconomy coverage:
Infinity Sees Comeback Potential for Cancer Drug That Failed
Infinity Pharma Lead Cancer Drug Trial Ends in Failure
Infinity Snags $75 Million Through Alliance With Purdue Pharma and Mundipharma … Next Page »

Single Page Currently on Page: 1 2 3 4 previous page

By posting a comment, you agree to our terms and conditions.